On 27 April 2015 the Board of Directors of Swedish Orphan Biovitrum AB (publ) (Sobi) confirmed that it had received a preliminary and conditional non-binding proposal in relation to a possible offer for all shares issued by the company. There can be no certainty that an offer will be made, nor as to the terms of any such offer.
In light of the above the Board of Sobi has decided to postpone the 2015 Annual General Meeting of Shareholders (AGM), scheduled for 6 May 2015, to 30 June 2015 in order to be able to provide as much clarity as possible by the time of the meeting. A separate notification for the rescheduled AGM will be published in due course.
Sobi will publish its interim report for the first quarter 2015 on 6 May 2015.
---
About Sobi
Sobi is an international specialty healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Haemophilia, Inflammation and Genetic diseases. We also market a portfolio of specialty and rare disease products for partner companies across Europe, the Middle East, North Africa and Russia. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2014, Sobi had total revenues of SEK 2.6 billion (USD 380 M) and about 600 employees. The share (STO: SOBI) is listed on NASDAQ Stockholm. More information is available at www.sobi.com.
For more information please contact
Media relations
Oskar Bosson, Head of Communications
T: +46 70 410 71 80
oskar.bosson@sobi.com
Investor relations
Jörgen Winroth, Vice President, Head of Investor Relations
T: +1 347-224-0819, +1 212-579-0506, +46 8 697 2135
jorgen.winroth@sobi.com
Sobi announces the information set out in this press release pursuant to the Swedish Securities Market Act. The information was submitted for publication at 08:05 CET on 29 April 2015.
013e_AGM postponed http://hugin.info/134557/R/1916235/685141.pdf
HUG#1916235
